



Dental Clinical Policy

Subject: Biological Materials to Aid in Soft Tissue and Osseous Tissue Regeneration (Endodontic)

Guidelines #: 03-401
Status: Revised

Publish Date: 01/01/2024
Last Review Date: 09/13/2023

Description

This document addresses the biological materials to aid in soft and osseous tissue regeneration whether used alone or in conjunction with other procedures. The field of tissue engineering or regenerative medicine is a process by which damaged tissues are regenerated rather than using grafts (autografts, allografts) by developing biological substitutes that restore, maintain or improve tissue function. In dentistry, adjunctive regenerative therapy utilizing biological materials can be used for the treatment of periodontal disease defects of natural teeth and recently dental implants

The plan performs review of Biological Materials to Aid in Soft and Osseous Tissue Regeneration due to contractual requirements that necessitate benefits for dental services meet specific contract requirements. For example, plan contract(s) may require the provision of benefits for services that meet generally accepted standards of dental care at the lowest cost that properly addresses the patient's condition. The conclusion that a particular service is medically or dentally necessary and/or appropriate does not constitute an indication and/or warranty that the service requested is a covered benefit payable by the dental plan.

Clinical Indications

Dental review as it applies to accepted standards of care means dental services that a Dentist, exercising prudent clinical judgment, provides to a patient for the purpose of evaluating, diagnosing or treating a dental injury or disease or its symptoms, and that are: in accordance with the generally accepted standards of dental practice; in terms of type, frequency and extent and is considered effective for the patient's dental injury or disease; and is not primarily performed for the convenience of the patient or Dentist, is not cosmetic and is not more costly than an alternative service.

For dental purposes, "generally accepted standards of dental practice" means:

- Standards that are based on credible scientific evidence published in peer-reviewed, dental literature generally recognized by the practicing dental community
- specialty society recommendations/criteria
- the views of recognized dentists practicing in the relevant clinical area
- any other relevant factors from credible sources

Criteria

When covered by specific group contract, indications for the use of biologic materials must be documented by:

1. Pretreatment periapical radiographic images that are of diagnostic quality, properly oriented, and identified, and dated current (within 12 months).
2. Current, dated periodontal charting (6-point periodontal charting as described by American Academy of Periodontology (AAP) and American Dental Association (ADA)) indicating a minimum of 5mm pocket depths.
3. A letter of rationale explaining the necessity of the regeneration procedure, and the type of material being used may be requested. For example, platelet rich plasma (PRP), Emdogain, recombinant human bone morphogenetic protein (rhBMP), Gem-21S, etc.
4. The use of biological materials may not be considered when used in conjunction with soft tissue grafting, bone grafts, guided tissue regeneration, ridge augmentation, periradicular surgery, placed within extraction sites, or when utilized with other regenerative materials regardless of specific group plan coverage.

Coding

The following codes for treatments and procedures applicable to this document are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

CDT including but not limited to:

D3431 Biologic materials to aid in soft and osseous tissue regeneration in conjunction with periradicular surgery

D4265 Biological material to aid in soft and osseous tissue regeneration, per site

ICD-10 CM Diagnoses for Dental Diseases and Conditions: See the current CDT code book for details

References

1. Parodi R, Liuzzo G, et al. Use of Emdogain in the treatment of deep intrabony defects: 12-month clinical results. Histologic and radiographic evaluation. Int J Perio Rest Dent 2000;19:93.

2. Giannobile W, Somerman M. Growth and amelogenin-like factors in periodontal wound healing. A systematic review. *Ann Periodontol* 2003;8:193-204.
3. CDT 2024 Current Dental Terminology, American Dental Association. McGuire MK and Scheyer ET. Xenogenic collagen matrix with coronally advanced flap compared to connective tissue with coronally advanced flap for the treatment of dehiscence-type defects. *J Perio* 2010; 81:1108-1117.
4. *Materials Today*, Volume 14, Issue 3, March 2011, pages 88-95: Biomaterials and Scaffolds for Tissue Engineering; Fergal J. O'Brien
5. Yassibag-Berkman Z, Tuncer O, et al. Combined use of platelet-rich plasma and bone grafting with or without guided tissue regeneration in the treatment of anterior interproximal defects. *J Perio* 2007; 78:801-809.
6. American Academy of Periodontology. AAP Commissioned Review. Bone augmentation techniques. *J Perio* 2007; 78:377-396.
7. American Academy of Periodontology. AAP Position Paper. Periodontal regeneration. *J Perio* 2005; 76:1621-1622.
8. Meyle J, Hoffman T, et al. A multi-center randomized controlled clinical trial on the treatment of intra-bony defects with enamel matrix derivatives/synthetic bone graft or enamel matrix derivatives alone. *J Clin Periodontol* 2011;38:652-660.
9. Sculean A, Windisch P and Chiantella GC. Human Histologic evaluation of an intrabony defect treated with enamel matrix derivative, xenografts, and GTR. *Int J Perio Rest Dent* 2004;24:326-333
10. Yukna RA and Mellonig JT. Histologic evaluation of periodontal healing in humans following regenerative therapy with enamel matrix derivative. A 10- case series. *J Perio* 2000; 71:752-759.
11. Yan X, Shao-Hua G, et al. A pilot study evaluating the effect of recombinant human bone morphogenic protein-2 and recombinant human beta-nerve growth factor on the healing of class III furcation defects in dogs. *J Perio* 2010; 81: 1289-1298.
12. Markous N, Pepelassi E, et al. The use of platelet--rich plasma combined with demineralized freeze-dried bone allograft in the treatment of periodontal endosseous defects. *J Amer Dent Assoc* 2010; 141:967-978.

History				
Revision History	Version	Date	Nature of Change	SME
	initial	2/8/17	creation	L Rosen

	Revision	2/6/18	Related policies, Appropriateness/Medical Necessity, criteria	M Kahn
	Revision	10/07/2020	Annual Review	Committee
	Revised	12/4/2020	Annual Review	Committee
	Revised	10/30/2021	Annual Review	Committee
	Revised	10/21/2022	Annual Review	Committee
	Revised	9/13/2023	Annual Review	Committee

Federal and State law, as well as contract language, takes precedence over Dental Clinical Policy. Dental Clinical Policy provides guidance in interpreting dental benefit application. The Plan reserves the right to modify its Dental Clinical Policies and guidelines periodically and as necessary. Dental Clinical Policy is provided for informational purposes and does not constitute medical advice. These Policies are available for general adoption by any lines of business for consistent review of the medical or dental necessity and/or appropriateness of care of dental services. To determine if a review is required, please contact the customer service number on the member's card.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the Plan.

Current Dental Terminology - CDT © 2024 American Dental Association. All rights reserved.